Your browser doesn't support javascript.
loading
Assessment of a Manual Method versus an Automated, Probability-Based Algorithm to Identify Patients at High Risk for Pharmacogenomic Adverse Drug Outcomes in a University-Based Health Insurance Program.
Grande, Kendra J; Dalton, Rachel; Moyer, Nicolas A; Arwood, Meghan J; Nguyen, Khoa A; Sumfest, Jill; Ashcraft, Kristine C; Cooper-DeHoff, Rhonda M.
Afiliación
  • Grande KJ; Invitae, Denver, CO 80134, USA.
  • Dalton R; Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA.
  • Moyer NA; Invitae, Seattle, WA 98121, USA.
  • Arwood MJ; Tabula Rasa Healthcare, Moorestown, NJ 08057, USA.
  • Nguyen KA; Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA.
  • Sumfest J; GatorCare, University of Florida, Gainesville, FL 32610, USA.
  • Ashcraft KC; Invitae, Seattle, WA 98121, USA.
  • Cooper-DeHoff RM; Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA.
J Pers Med ; 12(2)2022 Jan 26.
Article en En | MEDLINE | ID: mdl-35207649
We compared patient cohorts selected for pharmacogenomic testing using a manual method or automated algorithm in a university-based health insurance network. The medication list was compiled from claims data during 4th quarter 2018. The manual method selected patients by number of medications by the health system's list of medications for pharmacogenomic testing. The automated method used YouScript's pharmacogenetic interaction probability (PIP) algorithm to select patients based on the probability that testing would result in detection of one or more clinically significant pharmacogenetic interactions. A total of 6916 patients were included. Patient cohorts selected by each method differed substantially, including size (manual n = 218, automated n = 286) and overlap (n = 41). The automated method was over twice as likely to identify patients where testing may reveal a clinically significant pharmacogenetic interaction than the manual method (62% vs. 29%, p < 0.0001). The manual method captured more patients with significant drug-drug or multi-drug interactions (80.3% vs. 40.2%, respectively, p < 0.0001), higher average number of significant drug interactions per patient (3.3 vs. 1.1, p < 0.0001), and higher average number of unique medications per patient (9.8 vs. 7.4, p < 0.0001). It is possible to identify a cohort of patients who would likely benefit from pharmacogenomic testing using manual or automated methods.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Pers Med Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Pers Med Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos